Cyanobacteria - A novel source of pharmaceuticals

Current Opinion in Drug Discovery and Development

Volumn 1, Issue 1, 1998, Pages 77-84

  Jaspars, Marcel ^a,b   Lawton, Linda A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002675854     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cragg GM, Newman DJ, Snader KM: Natural products in drug discovery and development. J Nat Prod (1997) 60:52-60. A key review on the applications of natural products to drug development.
2. Cannell RJP, Owsianka AM, Walker JM: Results of a largescale screening programme to detect antibacterial activity from freshwater algae. BrPhycolJ'(1988) 23:41-44.
3. Honkanen RE, Caplan FR, Baker KK, Baldwin CL, Bobzin SC, Bolis CM, Cabrera GM, Johnson LA, Jung JH, Larsen LK, Levine IA, Moore RE, Nelson CS, Patterson GML, Tschappal KD, Tuang GD, Boynton AL, Arment AR, An J, Carmichael WW, Rodland KD, Magun BE, Lewin RA: Protein phosphatase inhibitory activity in extracts of cultured blue-green algae (cyanophyta). JPhycol'(1995) 31:478-486. This is a good example of a large well managed screening program that lead to the discovery of compounds such as the cryptophycins.
4. Moore RE, Patterson GML, Carmichael WW: New pharmaceuticals from cultured blue-green algae. Proc Cal Acad Sei (\<äW) 143-150.
5. Gerwick WH, Roberts MA, Proteau PJ, Chen J-L Screening cultured marine microalgae for anticancer-type activity. J App Phycol (1994) 6:143-149. A recent review on anticancer compounds derived from cyanobacteria.
6. Metting Jr F: Biodiversity and application of microalgae. J IndMicroblol (1996) 17:477-489.
7. Erhard M, von Dohren H, Jungblut P: Rapid typing and elucidation of new secondary metabolites of intact cyanobacteria using MALDI-TOF mass spectrometry. Nature Biotech (1997) 15:906-909. This is a key paper on novel methodology for investigating secondary metabolite content of intact cyanobacteria.
8. Schwartz RE, Hirsch CF, Sesin DF, Flor JE, Chartrain M, Fromtling RE: Pharmaceuticals from cultured algae. J Ind Microbiol(\ 990) 5:113-123.
9. Patterson GML, Baldwin CL, Bolis CM, Caplan FR, Karuso H, Larsen LK: Antineoplastic activity of cultured blue-greenalgae (cyanophyta). JPhycSW) 27:530-536.
10. Trimurtulu G, Ohtani I, Patterson GML, Moore RE, Corbett TH: Total structures of cryptophycins, potent antitumor depsipeptides. J Am Chem Ste(1994) 116:4729-4737. The initial paper reporting the discovery of the cryptophycins.
11. Golakoti T, Ogino J, Heltzel CE, Lehusebo T, Jehsen CM, Larsen LK: Structure determination, conformational-analysis, chemical stability studies, and antitumor evaluation of the cryptophycins-isolation of 18 new analogs from Nostoc sp strain GSV-224. J Am Chem 5oc(1995) 117:12030-12049.
12. Panda D, Himes RH, Moore RE, Wilson L, Jordan MA: Mechanism of action of the unusually potent microtubule inhibitor cryptophycin-1. Biochemistry (1997) 36:12948-12953.
13. Moobcrry SL, Busquets L: The initiation of apoptosis by cryptophycin, a new antimicrotubule agent. Mol Biol Cell (1996)7:263-263.
14. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapon Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in detection of antitumor activity in mice. Invest New Drugs (1997) 15:207-218. This publication indicates how the activity of the cryptophycins might have been missed if only one method of administration had been investigated.
15. Barrow RA, Hemscheidt T, Liang J, Paik S, Moore RE, This MA: Total synthesis of cryptophycins - revision of the structures of cryptophycin-A and cryptophycin-C. J Am Chem Sac (1995) 117:2479-2490.
16. Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate DL: Structure of curacin-A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. J Orff Chem (1994) 59:1243-45. The initial publication reporting the discovery ofcuracin A.
17. White JD, Kirn TS, Nambu M: Synthesis of curacin-A - a powerful antimitotic from the cyanobacterium Lyngbya majuscula. JAm Chem So
18. Verdier-Pinard P, Lai JY, Yoo HD, Yu JR, Marquez B, Nagle DG, Nambu M: Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharm (1998) 53:62-76.
19. Luduena RF, Prasad V, Roach MC, Banerjee M, Yoo HD, Gerwick WH: Interaction of the cyanobacterial thiazoline-containing lipid curacin-A with bovine brain tubulin. Drug Dev Res (1997) 40:223-229.
20. Rossi JV, Roberts MA, Yoo HD, Gerwick WH: Pilot scale culture of the marine cyanobacterium Lyngbya majuscula for its pharmaceutically-useful natural metabolite curacinA. JApp Pfiyco/(W97) 9:195-204. A prime example of exploiting the potential of cyanobacteria for the mass production of secondary metabolites.
21. Murakami M, Ishida K, Okino T, Okita Y, Matsuda H, Yamaguchi K: Aeruginosin-98-A and Aeruginosin-98-B, trypsin-inhibitors from the blue-green alga Microcystis aeruginosa(ti\ES-98). Tetrahedron Lett (1995) 36:2785-2788.
22. Murakami M, Okita Y, Matsuda H, Okino X Yamaguchi K: Aeruginosin 298-A, a thrombin and trypsin-inhibitor from the blue-green algae Microcystis aeruginosa (NIES-298). Tetrahedron Lett (1994) 35:3129-3132.
23. Sandier B, Murakami M, Clardy J: Atomic structure of trypsin-aeruginosin 98B complex. J Am Chem Soc (1998) 120:595-6. An investigation into the mode of action of the trypsin inhibitor aeruginosin 98B.
24. Rios Steiner JL, Murakami M, Tulinsky A: Structure of thrombin inhibited by aeruginosin 298-A from a blue green alga. JAm Chem Soc (1998) 120:597-8. An investigation into the mode of action of the thrombin inhibitor aeruginosin 298-A.
25. Shin HJ, Matsuda H, Murakami M, Yamaguchi K: Aeruginosins 205A and -B, serine proteinase inhibitory glycopeptides. J Org Chem (1997) 62:1810-1813.
26. Ishida K, Matsuda H, Murakami M, Yamaguchi K: Microginins 299-A and -B, leucine aminopeptidase inhibitors from the cyanobacterium Microcystis aeruginosa (NIES-299). Tetrahedron (1997) 53:10281-10288.
27. Moore RE: Cyclic-peptides and depsipeptides from cyanobacteria - a review. J IndMicroblol'(1996) 16:134-143.
28. Ishida K, Matsuda H, Murakami M, Yamaguchi K: Micropeptins 478-A and -B, plasmin inhibitors from the cyanobacterium Microcystis aeruginosa. J Nat Prod (1997) 60:184-187.
29. Murakami M, Kodani S, Ishida K, Matsuda H, Yamaguchi K: Micropeptin 103, a chymotrypsin inhibitor from the cyanobacterium Microcystis v//7Ws(NIES-103). Tetrahedron Lett (1997) 38:3035-3038.
30. Okino T, Qi S, Matsuda H, Murakami M, Yamaguchi K: Nostopeptins A and B, elastase inhibitors from the cyanobacterium Nostoc minutum. J Nat Prod'(1997) 60:158-161.
31. Shin HJ, Matsuda H, Murakami M, Yamaguchi K: Circinamide, a novel papain inhibitor from the cyanobacterium Anabaena circinalis (NIES-41). Tetrahedron (1997) 53:5747-5754.
32. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, Okeefe BR, Mori T et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimic Agents Chemother(W97) 41:1521-1530. An exciting publication on the discovery and potential applications of anti-HI V pep tide.
33. Mori T, Shoemaker RH, Gulakowski RJ, Krepps BL, McMahon JB: Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem Biophys Res Comm (1997) 238:218-222.
34. Mori T, Shoemaker RH, McMahon JB, Gulakowski RJ, Gustafson KR, Boyd: Construction and enhanced cytotoxicity of a [Cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Biochem Biophys Res Comm (1997) 239:884-888.
35. Gustafson KR, Cardellina JH, Fuller RW, Weislow OS, Kiser RF, Snader KM, Pattersön GML, Boyd MR: AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). J Nat Canc/nstC\9B9) 81:1254-1258.
36. Reshef V, Mizrachi E, Maretzki T, Silberstein C, Loya S, Hizi A, Carmeli S: New acetylated sulfoglycolipids and digalactolipids and related known glycolipids from cyanobacteria with a potential to inhibit reverse transcriptase of HIV-1. J Nat Prod (97) 60:1251-1260.
37. Colombo D, Scala A, Taino I, Toma L, Ronchetti F, Tokuda H, Nishino H, Nagatsu A, Sakakibara J: Inhibitory effects of fatty acid monoesters of 2-O-β-D-glucosylglycerol on Epstein Barr virus activation. Cancer Lett (1998) 123:83-86.